Clinical Trial Update: mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing mFOLFOX6 alone versus mFOLFOX6 combined with aflibercept as neoadjuvant therapy for MRI-defined T3 rectal cancer; study status completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer
• Rectosigmoid Cancer

Drugs mentioned

• Aflibercept (Aflibercept)
• MFOLFOX6

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: Rectal Cancer, Rectosigmoid Cancer | Phase 2 | Status: COMPLETED